AXL activation can drive cancer cell survival and proliferation through modulation of different signaling pathways, including the PI3K/AKT/mammalian target of rapamycin (mTOR), JAK/STAT, nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), and rat sarcoma virus/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase/extracellular signal-regulated kinases (RAS/RAF/MEK/ERK) pathways [67–69]. This evidence concerns the gene AKT1 and cancer.